Replimune REPL
- Market cap
- $1.8B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- −13.3%
Replimune's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $42.8M+42% | $42.6M+12% | $43M+6% | $43.4M−12% | $48M+12% | $54M+27% | $57.8M+35% | $57.9M+33% | $53.1M+11% | $52.3M−3% | $49.3M−15% | $34.4M−41% |
| SG&A | $13.7M+20% | $16.2M+8% | $14.4M−5% | $15.5M+5% | $18M+32% | $25.4M+57% | $32.6M+126% | $26.4M+71% | $18.7M+4% | $21M−17% | $19M−42% | $21.9M−17% |
| −$56.5M+36% | −$58.8M+11% | −$57.4M+3% | −$58.9M−8% | −$66M+17% | −$79.3M+35% | −$90.4M+58% | −$84.3M+43% | −$71.9M+9% | −$73.3M−8% | −$68.2M−25% | −$56.3M−33% | |
| Interest expense | $1.6M+4% | $2M+24% | $2M+18% | $2M+32% | $2M+27% | $2M+2% | $2M+2% | $2M+2% | $2M+0% | $2.9M+45% | $3.1M+55% | $3M+51% |
| Pre-tax income | −$50.6M+28% | −$55.1M+13% | −$53.8M+9% | −$53.1M−12% | −$65.8M+30% | −$74.2M+35% | n/a | n/a | −$71.2M+8% | −$73.5M−1% | n/a | n/a |
| $473K | −$65K | $0 | $0 | $575K+22% | −$107K+65% | n/a | n/a | −$311K | −$240K+124% | n/a | n/a | |
| Net income | −$51.1M+29% | −$55.1M+12% | −$53.8M+9% | −$53.1M−12% | −$66.3M+30% | −$74.1M+35% | −$86.7M+61% | −$83.1M+57% | −$70.9M+7% | −$73.2M−1% | −$69.8M−20% | −$57.1M−31% |
| −$0.77+12% | −$0.83+12% | −$0.78+4% | −$0.68−24% | −$0.79+3% | −$0.81−2% | −$0.95+22% | −$0.90+32% | −$0.77−3% | −$0.77−5% | −$0.72−24% | −$0.54−40% | |
| 66.6M+15% | 66.7M+1% | 69.2M+4% | 78.6M+18% | 83.5M+25% | 91.1M+37% | 91.5M+32% | 91.9M+17% | 92.2M+10% | 95.6M+5% | 96.9M+6% | 105.2M+14% |
Net income: 29 periods, Q2 FY20 to Q2 FY27: not printed by the filing, worked out from its own lines.
EPS, diluted: 8 periods, Q4 FY18 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: 9 periods, Q4 FY18 to Q4 FY26: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Replimune's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| REPLReplimune | $1.8B | n/m | n/a | n/m | n/m | n/m | |
| VCELVericel | $2.1B | 88.1× | 157× | 6.8× | +23% | 7.9% | |
| ADMAAdma Biologics | $2.5B | 15.8× | 21.3× | 4.8× | +8% | 33.0% | |
| MGTXMeiraGTx | $895.1M | 13.1× | 15.4× | 2.3× | n/m | 19.9% | |
| KRYSKrystal Biotech | $8.8B | 37.1× | 42.5× | 19.9× | +23% | 54.8% | |
| RGENRepligen | $9.8B | 237× | 123× | 12.4× | +16% | 5.3% | |
| TECHBIO-TECHNE | $11.4B | 63.2× | 62.0× | 9.4× | −0% | 15.0% | |
| HALOHalozyme Therapeutics | $14.6B | 38.5× | 21.3× | 8.8× | +41% | 24.9% | |
| NBIXNeurocrine Biosciences | $14.8B | 21.3× | 42.6× | 4.4× | +34% | 20.9% | |
| PLXProtalix BioTherapeutics | $206.3M | 11.1× | 33.6× | 2.6× | +30% | 23.5% | |
| EXELExelixis | $17.4B | 22.1× | 22.7× | 7.1× | +9% | 35.3% | |
| Peer median | $9.3B | 29.6× | 38.1× | 7.0× | +23% | 22.2% |
More on Replimune
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .